Choosing Between CROs and Biotechs: How Company Size Shapes the Fit

While biotechs and contract research organizations each have strengths, the article notes that the right choice depends on a company’s specific situation.

Ali Pashazadeh, founder and CEO of Treehill Partners, explains that employees at large global CROs typically provide input but do not make principal decisions about study design or indication selection. In contrast, biotech staff drive those decisions and bear the risk of the company’s success or failure.

The piece also highlights perceived benefits of CROs such as a variety of projects, greater stability and career opportunities, citing Egle Pavyde of APICES as an example of CRO leadership.